Baxdrostat is a highly selective, second-generation, nonimidazole aldosterone synthase inhibitor; 100 times less baxdrostat ...

An international research team led by CIC bioGUNE has advanced understanding of classical homocystinuria, a rare genetic disorder that impairs the breakdown of homocysteine, causing systemic health ...

High-resolution cryo-electron microscopy makes it possible to study complex enzymatic processes in detail. With this method, ...

AZN hits all endpoints in phase III study for baxdrostat, a first-in-class treatment targeting hard-to-manage hypertension.

Topline data were announced from a phase 3 trial that evaluated baxdrostat in patients with uncontrolled or treatment resistant hypertension.

AstraZeneca announced that baxdrostat, a selective aldosterone synthase inhibitor, met its primary and all secondary ...

In the realm of peptide-based research, few compounds have garnered as much interdisciplinary interest as BPC-157. This ...

Key TakeawaysErythritol damages brain blood vessel cells, increasing risk of blood clots and stroke in lab studies. It ...

A phase 2 trial evaluated the efficacy and safety of lorundrostat in hypertensive patients with chronic kidney disease (CKD) and albuminuria.

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...